Previous Close | 9.55 |
Open | 9.80 |
Bid | 8.61 x 800 |
Ask | 8.91 x 900 |
Day's Range | 8.58 - 9.80 |
52 Week Range | 8.51 - 30.89 |
Volume | |
Avg. Volume | 39,201 |
Market Cap | 240.605M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.66 |
Earnings Date | May 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for TKNO
First quarter 2022 total revenue was $11.1 million, up 23% year-over-yearExcluding Sample Transport revenue, first quarter 2022 total revenue was $11.1 million, up 37% year-over-yearStrong cash position of $76.5 million supports investment in growth strategy HOLLISTER, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecula
HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2022, on Wednesday, May 11, 2022, following the close of market. Teknova will host a webcast and conference call on Wednesday, May 11, 2022
Full year 2021 total revenue was $36.9 million, up 18% year-over-yearExcluding Sample Transport revenue of $1.5 million, full year 2021 total revenue was $35.4 million, up 31% year-over-yearCompany provides 2022 revenue guidance of $44-$48 millionHOLLISTER, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnost